ImmuPharma PLC
IMM.L - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.06B
Close$
$0.28
92.5% downside
Current Fair Value
92.5% downsideOvervalued by 92.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.06 Billion |
|---|---|
| Enterprise Value | $2.05 Billion |
| Earnings per Share | $0 |
| Beta | 3.02 |
| Outstanding Shares | 559,335,786 |
Return
| Return on Equity | -385.44% |
|---|---|
| Return on Assets | -226.67% |
| Return on Invested Capital | -195.42% |
Valuation & Multiples
| P/E Ratio | -3.04 |
|---|---|
| PEG | -0.74 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -576.99 |
| Enterprise Value to Net Income | -293 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 24, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
May 25, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About ImmuPharma PLC
7 employees
CEO: Timothy Paul McCarthy
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The com...